Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies.

From the knowledge gained in developing recombinant vaccines successfully since 1994, and having gained considerable experience in improving the technology processes of those products, Transgene has expanded its product portfolio to other therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others.

In line with its expanded product development portfolio, Transgene is modifying its existing infrastructure to cater to further Research & Development activities and is presently constructing a new manufacturing facility to meet WHO and US FDA standards.  Transgene is focused on maximizing synergies through strategic partnerships. We are excited to explore opportunities with partners and catalyze technological advances in the field of biotechnology.   Since 1994, Transgene Biotek has developed or has been involved in the development of technology for several different bio-pharmaceuticals, recombinant vaccines and therapeutics. We have extensive experience and expertise to assist you in recombinant drug development, characterization, testing and validation.

Product range of the company includes:

The company is engaged in manufacturing drugs for:

New Drug Delivery System (NDDS)

• Oral Delivery of Insulin
• Oral Delivery Hepatitis B Vaccine
• Pegylation of Protein Drugs for Sustained Release

Biogeneries

• Tacrolimus 
• Pegylated EPO 

Human Vaccines

• Meningococcal Meningitis
• Universal Meningococcal Meningitis
• Haemophilus Influenza B-Hib
• DTP+Hib+Hep B Combination
•  Hepatitis A+B Combination 

Cancer Drugs/Oncology

• Multiple Myeloma
• Barrett's Esophageal Cancer
• Colon Cancer
• Breast Cancer